Glenmark制药公司报告,Q2利润丰厚,达354.5克朗,扭转了去年的损失。 Glenmark Pharmaceuticals reports a strong Q2 profit of ₹354.5 crore, reversing last year's loss.

Glenmark制药公司在Q2FY25中出现了显著的转折,报告净利润为354.5克朗,而去年的亏损为180.3克朗。 Glenmark Pharmaceuticals saw a significant turnaround in Q2FY25, reporting a net profit of ₹354.5 crore compared to a ₹180.3 crore loss last year. 在印度和欧洲的强劲销售推动下,收入增长7%,达到3 434克郎。 Revenue rose 7% to ₹3,434 crore, driven by strong sales in India and Europe. 该公司的龙头呼吸系统品牌RYALTRIS继续表现良好。 The company's flagship respiratory brand, RYALTRIS, continued to perform well. Glenmark计划在下一个季度推出3-4种新产品,目标是当年收入在13 500克罗里和14 000克罗里之间。 Glenmark plans to launch 3-4 new products in the next quarter and aims for revenue between ₹13,500 crore and ₹14,000 crore for the year.